Vascular regeneration, umbilical cord blood, peripheral blood

Cell therapy, regenerative medicine

Hematopoietic cells are a cell source for angiogenesis therapy targeting ischemic diseases. The hematopoietic cells used are derived from the red blood cell-removed fraction or mononuclear cell fraction of bone marrow aspirate, umbilical cord blood, or peripheral blood. Specifically, studies have been conducted using CD34-positive cells and endothelial progenitor cells (EPCs) isolated from the mononuclear cell fraction, or the mononuclear cell fraction itself. However, the angiogenic effect of these hematopoietic cells is still insufficient. By co-culturing these hematopoietic cells with OP9 feeder cells, we have confirmed that within 24 hours, (1) cell death of hematopoietic cells is reduced, (2) stress on the cultured hematopoietic cells is reduced, (3) the hematopoietic cells form a cell network, (4) the proportion of M2 macrophages is increased in the produced hematopoietic cell population, and (5) the angiogenic effect and attenuation of the sequelae of cerebral infarction by cell transplantation in a mouse cerebral infarction model (Sci Rep. 2023 Jan 6;13(1):262.). Furthermore, we have discovered that culturing blood lineage cells in OP9 culture supernatant can induce M2 macrophage differentiation in blood lineage cell populations, and have patented this finding (Patent Application No. 2022-154854).

We found that it is possible to establish blood lineage cells that induce angiogenesis by co-culturing blood lineage cells with OP9 feeder cells.

• AiC, including induction of M2 macrophages, can be established within a very short period of time, within 24 hours.
• This method can be applied not only to umbilical cord blood but also to blood cells such as peripheral blood and bone marrow.
• It is expected that this technology will be applied to various diseases for which M2 macrophages can be expected to have a therapeutic effect.

It has been found that revascularization after cerebral infarction contributes to intrinsic nerve function, and it is expected that AiC will be effective in restoring nerve function after cerebral infarction.

• Ischemic diseases in general (cerebral infarction, myocardial infarction, lower limb ischemia, etc.)
• Diseases in which M2 macrophages can contribute to improving pathology (collagen diseases, interstitial pneumonia, hepatitis, nephritis, etc.)

Patent application 2022-154854 "Method for producing cell populations that induce angiogenesis"

1. Sci Rep. 2023 Jan 6;13(1):262.
2. 22nd Annual General Meeting of the Japanese Society for Regenerative Medicine March 2023